Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
ConclusionsPatients with PsA who switched to another TNFi had lower total healthcare expenditures and longer persistence compared with patients who switched to a non-TNFi biologic.FundingAbbVie.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Arthritis | Databases & Libraries | Dermatology | Enbrel | Humira | Psoriatic Arthritis | Remicade | Rheumatology | Skin | Stelara | Study | USA Health